University of Reading Featured PhD Programmes
Queen’s University Belfast Featured PhD Programmes
University of Cambridge Featured PhD Programmes

ADOPT 2: Precision drug dosing for cancer patients using simple, home-based pharmacokinetic profiling


   School of Medicine

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr C Proby  No more applications being accepted  Funded PhD Project (Students Worldwide)

Dundee United Kingdom Cancer Biology Pharmacology

About the Project

Division: Molecular and Clinical Medicine

Start Date: 20/09/21

This clinical training fellowship is truly translational with potential to immediately improve the clinical management of cancer patients through a precision medicine approach to drug dosing. 

Many targeted anti-cancer drugs have been developed using maximal tolerated dose instead of pharmacological potency, leading to much higher doses than those predicted to be effective, causing unnecessary toxicity. Furthermore, these drugs are often potent inducers or inhibitors of the cytochrome P450 system responsible for the metabolism and disposition of almost all drugs. This can lead to adverse interactions with other anti-cancer therapies, or with drug combinations, which may be rendered ineffective or not tolerated. To improve cancer care, we need to do better than this ‘one-size fits all’ approach. We must measure drug exposure during treatment to ensure concentrations lie within the ‘therapeutic window’. 

In a feasibility study (ADOPT 1), we have shown that a simple finger-prick blood spot test (BST) can be used to analyse plasma drug levels in cancer patients. Using a combination of BST drug-profiling, Mass Spec measurement of plasma drug levels and a unique P450 humanised mouse model (8HUM), the clinical fellow will address whether therapeutic drug monitoring will lead to improved tolerability and efficacy for anti-cancer therapies. The fellow will examine variability in drug exposure in cancer patients and evaluate how this relates to BMI, frailty, clinical outcomes and drug interactions. They will also study whether studies using 8HUM mice predict what is seen clinically.   

Apply

Applicants to complete the Application form and email to [Email Address Removed] along with a CV and 2 academic references by Monday 22nd March 2021.

Eligibility Requirements

First class honours degree, and/or a Masters degree in a relevant discipline. (Non-clinical applicants)

MBChB (clinical applicants)

English language requirements

IELTS minimum overall score of 6.5

Reading 5.5, Listening 5.5, Speaking 5.5 Writing 6.0


Funding Notes

Funded by the Ninewells Cancer Campaign
RCUK stipend rate for 4 years (non-clinical applicants)
or
University of Dundee Clinical Research Fellow scale for 3 years (clinical applicants)
Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.